A5030489879- Retinal Diseases and Treatments
- Retinal Imaging and Analysis
- Retinal and Optic Conditions
- Retinal and Macular Surgery
- Glaucoma and retinal disorders
- Ocular Diseases and Behçet’s Syndrome
- Intraocular Surgery and Lenses
- Vascular Malformations Diagnosis and Treatment
- Optical Coherence Tomography Applications
- Corneal surgery and disorders
- Retinal Development and Disorders
- Financial Literacy, Pension, Retirement Analysis
- Intracranial Aneurysms: Treatment and Complications
- Ophthalmology and Visual Impairment Studies
- Private Equity and Venture Capital
- Ocular Infections and Treatments
- Botulinum Toxin and Related Neurological Disorders
- Sarcoidosis and Beryllium Toxicity Research
- Traumatic Ocular and Foreign Body Injuries
- Head and Neck Surgical Oncology
- Corneal Surgery and Treatments
- Healthcare Policy and Management
- Retinopathy of Prematurity Studies
- Cerebral Venous Sinus Thrombosis
- Complement system in diseases
California Retina Consultants
2016-2025
Allergan (Ireland)
2015
Novartis (Switzerland)
2015
Regeneron (United States)
2015
Retina Research Foundation
2015
ViteroRetinal Surgery
2013
Cleveland Eye Clinic
2011-2012
Cleveland Clinic
2011-2012
Imaging Center
2012
Oregon Health & Science University
2007-2010
<h3>Background</h3> Data comparing systemic exposure and vascular endothelial growth factor (VEGF) suppression of ranibizumab, bevacizumab aflibercept following intravitreal injection are lacking. <h3>Methods</h3> Fifty-six patients with wet age-related macular degeneration received ranibizumab (0.5 mg), (1.25 or (2.0 mg). Serum pharmacokinetics plasma free VEGF were evaluated after the first third injections. <h3>Results</h3> Following dose, to was 5-, 37-, 9-fold higher than whereas, 9-,...
Purpose: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic edema (DME), or retinal vein occlusion (RVO). Methods: Prospective, open-label, nonrandomized clinical trial AMD, DME, RVO who were antivascular endothelial growth factor (VEGF) naïve had not received anti-VEGF for ≥4 months. Patients 3 monthly intravitreal injections aflibercept 2.0 mg, bevacizumab 1.25 (0.5 mg...
PurposeTo compare the efficacy and safety of brolucizumab with aflibercept in patients diabetic macular edema (DME).DesignDouble-masked, 100-week, multicenter, active-controlled, randomized trials.MethodsSubjects were 1:1:1 to 3 mg/6 mg or 2 KESTREL (n = 566) 1:1 6 KITE 360). Brolucizumab groups received 5 loading doses every weeks (q6w) followed by 12-week (q12w) dosing, optional adjustment 8 (q8w) if disease activity was identified at predefined assessment visits; 4 (q4w) fixed q8w dosing....
<h3>Objective</h3> To describe the choroidal characteristics of patients with retinitis pigmentosa (RP) using enhanced depth imaging (EDI) and spectral domain (SD) optical coherence tomography (OCT). <h3>Purpose</h3> investigate spectral-domain ocular features choroid in RP EDI. <h3>Methods</h3> A prospective, case–control study 21 from Cole Eye Institute imaged Spectralis OCT an EDI protocol. Submacular thickness measurements were obtained beneath fovea at 500 µm intervals for 2.5 mm nasal...
Identifying the factors that are associated with magnitude of treatment benefits from anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) may help refine expectations.To identify baseline vision and anatomic outcomes when managing DME anti-VEGF determine if there interactions between agent administered.This post hoc analysis data Diabetic Retinopathy Clinical Research Network multicenter randomized clinical trial , Protocol T, was conducted December...
PurposeTo report the 100-week outcomes from KESTREL and KITE.DesignTwo phase 3, double-masked, active-controlled, randomized trials.MethodsPatients with diabetic macular edema (DME) were 1:1:1 to brolucizumab 3 mg/6 mg (BRO3/BRO6) or aflibercept 2 (AFL) in (N=566) 1:1 BRO6 AFL KITE (N=360). BRO3/BRO6 arms received 5 loading doses every 6 weeks (q6w) followed by q12w dosing, an option adjust q8w at predefined disease activity assessment visits. In KITE, Week 72, based on stability assessment,...
First published in 1970, the Gass Atlas of Macular Diseases has become a trusted reference for ophthalmologists worldwide. The fifth edition edited by Dr Anita Agarwal, continues to share …
To evaluate the intraoperative and early postoperative outcomes of Descemet stripping automated endothelial keratoplasty (DSAEK) in patients with previous glaucoma filtering surgeries.A retrospective review all DSAEK surgeries performed at one center comparing complications eyes procedures (study eyes) a time-matched group other cases (control eyes).There were 28 study eyes, 19 trabeculectomies 9 drainage devices (GDDs) 431 control eyes. Study included 1 compromised bleb loss donor tissue...
In Brief Purpose: To assess the posterior vitreous release rates following a single, office-based intravitreal injection of expansile gas in treating vitreomacular traction. Methods: Thirty eyes 29 consecutive patients with symptomatic traction received up to 0.3 mL 100% perfluoropropane (C3F8). Results: Overall, occurred 25 30 by final follow-up visit (83% rate); furthermore, 90% (9 10 eyes) diabetes mellitus released, 83% (5 6 concurrent epiretinal membrane and previously treated...
Despite its off-label status, intravitreal bevacizumab is the most commonly used intraocular anti-vascular endothelial growth factor agent. Regulation of compounding pharmacies has recently increased to make compounded pharmaceuticals safer. these changes, a marked increase in symptomatic, large silicone oil droplets following injections was noticed.Retrospective chart review performed. Within single private practice, patients who were noted have or symptomatic bubbles after an injection...
To evaluate the effect of baseline subretinal fluid (SRF) on treatment outcomes with intravitreal aflibercept injection (IAI) versus laser in patients diabetic macular edema (DME) VIVID and VISTA studies. Post hoc analysis 2 randomized controlled trials. Eight hundred seventy-two DME. We to receive IAI mg every 4 weeks (2q4), 8 after 5 monthly doses (2q8), or laser. Effect presence absence SRF visual integrated dataset at 52 100. Mean best-corrected acuity (BCVA) gains 2q4, 2q8, arms week...
To report initial experience with intravitreal ocriplasmin (IVO) and to describe outer retina reflectivity changes observed on spectral domain optical coherence tomography (SD-OCT) after IVO injection in patients vitreomacular traction (VMT) or without macular holes (MHs).A consecutive retrospective review of VMT MH who were treated was performed. Patients underwent complete ophthalmic evaluation, including nonstandardized Snellen visual acuity testing, SD-OCT at baseline follow-up visits.A...
To establish the safety, tolerability, pharmacokinetics, and pharmacodynamics of an intravitreal injection recombinant human complement factor H (CFH), GEM103, in individuals with genetically defined age-related macular degeneration (AMD) geographic atrophy (GA).Phase I single ascending-dose, open-label clinical trial (ClinicalTrials.gov identifier, NCT04246866).Twelve 50 years age or older a confirmed diagnosis foveal GA study eye.Participants were assigned to increasing dose cohorts...
Abstract Objectives To determine the relationship between treatment frequency with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and visual acuity (VA) outcomes in eyes macular oedema (MO) secondary to branch retinal vein occlusion (BRVO) US clinical practice. Methods Study that initiated anti-VEGF injections January 2012 May 2016 were followed for ≥1 year a retrospective analysis of medical records (Vestrum Health database). Eyes analysed 2 cohorts by duration...
To evaluate rates of suspected endophthalmitis following intravitreal injections aflibercept, bevacizumab, ranibizumab (vial and pre-filled), dexamethasone implant, triamcinolone in clinical practice.Retrospective study aggregated electronic medical records from the Vestrum Health Database. Eyes with a diagnosis based on billing codes between January 2013 June 2019 were included.Total number injections, cases, medication rate, respectively, were: aflibercept (1,412,699; 687; 0.049%);...